Gene therapy company Vigene Biosciences has announced the appointment of Dr. Audrey Chang as VP of QC and Analytical Services.
"Vigene Biosciences continues our successful growth trajectory; and we are very excited about the addition of Dr. Audrey Chang to our leadership team,” said Vigene Biosciences President and CEO Dr. Zairen Sun. “Dr. Chang is a thought leader and experienced executive for cell and gene therapy QC and analytical testing. I am confident that her addition will greatly enhance Vigene's capacity and capabilities in QC and analytical assays to meet the increasing demand for viral vector and plasmid manufacturing and analysis."
Dr. Chang is a world renowned biologics QC and analytical testing expert, with more than 20 years of experience leading QC development at BioReliance/MilliporeSigma. She has authored more than 15 papers and is a respected keynote speaker at conferences and meetings.
"Gene therapy manufacturing and analytical services should be integrated to accelerate the pace of availing gene therapy products to clinical trials and patients,” said Dr. Chang. “I am excited to join Vigene to bring best in class service offerings for viral vector and plasmid manufacturing and analytics."